
Jazz Pharmaceuticals Defies Expectations: What This Means for Investors
Jazz Pharmaceuticals reported strong Q4 sales of $1.09 billion, surpassing analyst expectations with a 7.5% year-over-year increase. Earnings per share (EPS) reached $6.60, exceeding forecasts by 13.6% and showcasing significant profitability growth. The company projects $4.28 billion in revenue for the coming